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Monoamine oxidases are novel sources of cardiovascular 
oxidative stress in experimental diabetes1
Adrian Sturza, Oana M. Duicii, Adrian Vaduva, Maria D. Danila, Lavinia Noveanu, András Varró, 
and Danina M. Muntean
Abstract: Diabetes mellitus (DM) is widely recognized as the most severe metabolic disease associated with increased cardio­
vascular morbidity and mortality. The generation of reactive oxygen species (ROS) is a major event causally linked to the 
development of cardiovascular complications throughout the evolution of DM. Recently, monoamine oxidases (MAOs) at the 
outer mitochondrial membrane, with 2 isoforms, MAO-A and MAO-B, have emerged as novel sources of constant hydrogen 
peroxide (H20 2) production in the cardiovascular system via the oxidative deamination of biogenic amines and neurotransmit- 
ters. Whether MAOs are mediators of endothelial dysfunction in DM is unknown, and so we studied this in a streptozotocin- 
induced rat model of diabetes. MAO expression (mRNA and protein) was increased in both arterial samples and hearts isolated 
from the diabetic animals. Also, H20 2 production (ferrous oxidation -  xylenol orange assay) in aortic samples was significantly 
increased, together with an impairment of endothelium-dependent relaxation (organ-bath studies). MAO inhibitors (clorgyline 
and selegiline) attenuated ROS production by 50% and partially normalized the endothelium-dependent relaxation in diseased 
vessels. In conclusion, MAOs, in particular the MAO-B isoform, are induced in aortas and hearts in the streptozotocin-induced 
diabetic rat model and contribute, via the generation of H20 2, to the endothelial dysfunction associated with experimental 
diabetes.
Keywords: monoamine oxidases, experimental diabetes mellitus, oxidative stress, endothelial dysfunction, clorgyline, selegiline.
Résumé : Il est largement accepté que le diabète sucré est la maladie métabolique la plus grave, associée à une morbidité et une 
mortalité cardiovasculaires. La production de dérivés réactifs de l’oxygène (DRO) est une manifestation majeure entraînant des 
complications cardiovasculaires tout au long de la progression du diabète sucré. Récemment, les monoamine oxydases (MAO) de 
la membrane mitochondriale externe sous deux isoformes (MAO-A et MAO-B) se sont démarquées comme de nouvelles sources 
de production constante de peroxyde d’hydrogène (H20 2) dans le système cardiovasculaire par l’intermédiaire de la désamina­
tion oxydative des amines biogènes et des neurotransmetteurs. On ne sait pas si les MAO sont des médiateurs de la dysfonction 
endothéliale dans le diabète sucré, et c’est ce que nous avons étudié avec ce modèle de diabète induit par la streptozotocine chez 
le rat. L’expression des MAO (ARNm et protéines) augmentait dans les échantillons artériels comme dans les cœurs isolés 
d’animaux diabétiques. De plus, la production de H20 2 (test de l’oxydation des ions ferreux révélée par le xylénol orange) dans 
des échantillons d’aorte était nettement accrue et associée à un déficit de la relaxation dépendante de l’endothélium (études en 
bain d’organe). L’administration des inhibiteurs des MAO (clorgyline et sélégiline) a permis de diminuer la production de DRO 
de 50 % et est parvenue en partie à rétablir la relaxation dépendante de l’endothélium à une valeur normale dans les vaisseaux 
atteints. En conclusion, dans le modèle de diabète induit par la streptozotocine chez le rat, les MAO, en particulier l’isoforme 
MAO-B, sont induites dans les aortes et les cœurs des animaux et contribuent par la production de H20 2 à la dysfonction 
endothéliale observée dans un modèle expérimental du diabète. [Traduit par la Rédaction]
Mots-de's : monoamine oxydases, diabète sucré expérimental, stress oxydatif, dysfonction endothéliale, clorgyline, sélégiline.
Introduction
Diabetes mellitus (DM), the most severe metabolic disease asso­
ciated with increased cardiovascular morbidity and mortality, is 
widely recognized nowadays as a serious threat to global health, 
owing to its escalating prevalence worldwide (Guariguata et al. 
2014).
The generation of reactive oxygen species (ROS) is a m ajor 
event tha t is causally linked to the developm ent of cardiovas­
cular com plications th roughout the evolution of DM; however, 
the pathophysiological m echanisms underlying both diabetic
cardiomyopathy and diabetes-related endothelial dysfunction are 
far from being fully elucidated (Joshi et al. 2014).
Monoamine oxidases (MAOs) are ubiquitous dehydrogenases lo­
cated at the outer mitochondrial m em brane that catalyze the 
oxidative deamination of neurotransm itters and dietary amines 
with the constant generation of hydrogen peroxide (H20 2), am mo­
nia, and aldehydes as by-products o f their catalytic cycle (Shih 
et al. 1999; Edmondson 2014). Two isoenzymes with different tis­
sue distribution and sensitivity to pharmacological inhibition are 
described: the MAO-A isoform, which is irreversibly inhibited by
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clorgyline, and the MAO-B isoform, which is irreversibly blocked 
by low doses of selegiline (reviewed in Bortolato et al. 2008).
For more than half centuiy, MAOs have been recognized as 
major contributors to the pathogenesis o f hum an neurodegenera- 
tive and depressive disorders, and both irreversible and reversible 
pharmacological inhibitors have unequivocally proven their ther­
apeutical properties in these settings (Al-Nuaimi et al. 2012; Song 
et al. 2013; Youdim et al. 2006).
However, during the past decade, MAOs have also emerged as 
im portant m itochondrial sources of oxidative stress in the cardio­
vascular system (for an excellent recent review of the topic see 
Kaludercic et al. 2014b).
In the heart, MAO-related oxidative stress contributes to the 
cell death triggered by myocardial ischem ia-reperfusion injury 
(Bianchi et al. 2005), to mitochondrial dysfunction, and to mal­
adaptive evolution of cardiac hypertrophy to heart failure (Kaludercic 
et al. 2010, 2014a).
W ith reference to the vascular system, in-vitro or in-vivo appli­
cation o f the irreversible MAO-B inhibitor selegiline elicited vaso­
dilation via an increase in the am ount o f NO in cerebral arteries 
(Thomas et al. 1998). Also, MAO-A was found to be overexpressed 
in basilar arteries isolated from spontaneously hypertensive rats, 
together w ith increased H20 2 generation, an effect that was sen­
sitive to the irreversible MAO-A inhibitor clorgyline (Poon et al. 
2010).
Information regarding the contribution of MAOs to oxidative 
stress in the setting of diabetes is rather limited. Using a strepto- 
zotocin model of experimental diabetes, Manni et al. (2013) re­
ported increased MAO-A activity in cardiomyocytes in response to 
the up-regulation o f the  ren in-angio tensin  system. Similarly, 
we found increased H20 2 generation in aortic rings harvested 
from Zucker diabetic fatty rats (ZDF), a genetic model of type-2 
diabetes, that significantly diminished in the presence of clorgy­
line (Sturza et al. 2014).
The aim of this study was to investigate the role o f MAOs as 
contributors to oxidative stress in the streptozotocin-induced rat 
model of diabetes.
Materials and methods
Six-week-old male W istar rats were purchased from the Canta- 
cuzino Institute (Bucharest, Romania) and were acclimated for 
2 weeks prior to the study. At the age of 8 weeks, diabetes was 
induced by a single intraperitoneal (i.p.) injection of streptozoto- 
cin (STZ; 50 mg/kg body mass). Age-matched control rats received 
an equal volume of vehicle (0.01 mol/L citrate buffer, pH 4.5). Two 
days after the injection, a blood sample was collected from the tail 
vein to measure the blood glucose. Rats w ith a blood glucose level 
over 200 mg/dL were considered diabetic. Animals were housed 
under standard conditions (constant tem perature of 22.5 ± 2 °C, 
humidity 55% + 5%, w ith a 12 h (light) -12  h (dark) cycle). Diabetes 
developed over a 2 m onth period, and glycemia and body mass 
were systematically monitored. Twenty-four hours prior to the 
experiment, solid food was withdrawn but there was no lim ita­
tion in water supply.
All experimental procedures used in this study were conducted 
in accordance w ith EU Directive 2010/63/EU and the Romanian 
Law No. 43/May 2014, concerning the protection of animals used 
for scientific purposes. The experimental protocol was approved 
by the Committee for Research Ethics o f “Victor Babe$” University 
for Medicine and Pharmacy.
All reagents used were of the h ighest quality available and 
were purchased from Sigma-Aldrich, Invitrogen, Applichem, or 
Abeam.
ROS measurement
Hydrogen peroxide production was assessed in aortic rings har­
vested from animals w ith or without diabetes in the presence, 
compared w ith the absence, o f MAO inhibitors (30 m in preincu­
bation with 10 |xmol/L clorgyline or selegiline) by means of the 
ferrous iron -  xylenol orange oxidation (FOX) assay, using a Per- 
oxiDetect Kit (Sigma-Aldrich). The principle of the assay is that 
peroxides oxidize Fe2+ to Fe3+ ions at acidic pH. The Fe3+ ion will 
form a colored adduct w ith xylenol orange (XO; 3,3'-bis[N,N- 
bis(carboxymethyl)aminomethyl]-o-cresolsulfonephthalein; sodium 
salt), which can be observed at 560 nm.
Organ-bath studies
Organ-bath experiments were performed in rat aortic rings in 
the presence of diclofenac (10 pmol/L). The concentration of 
phenylephrine used for preconstriction was adjusted to obtain a 
preconstriction level of 80% of the contraction elicited by KC1 
(80 mmol/L). Endothelium-dependent relaxation to cumulative 
concentrations of acetylcholine (Ach) was recorded in the pres­
ence or absence of MAO inhibitors (10 |xmol/L clorgyline or 
selegiline).
Real-time polymerase chain reaction (RT-PCR)
Quantitative RT-PCR was performed as previously described 
(Sturza et al. 2013a). Primers against MAO isoforms were designed 
using the sequence information (5'-3') for rat from the NCBI da­
tabase. MAO-A: forward, TCT CAG GAT TGG CTG CTG CCA AAC; 
reverse, CAG GTG GAA ATG CAC CAC GGAATG. MAO-B: forward, 
TGG GCC AAG AGA TTC CCA GTG ATG; reverse, AGA GCG TGG 
CAA TCT GCT TTG TAG. The sequence numbers from the NCBI 
database for the preparation of MAO-A and MAO-B primers were 
NM_173740.3 for MAO-A and NM_172778.2 for MAO-B. The house­
keeping gene and its primers were as follows: EEF2a, forward 
5'-GACATCACCAAGGGTGTGCAG-3'; reverse 5'-GCGGTCAGCACA 
CTGGCATA-3'. Total RNA was isolated from aortic rings and cells 
w ith the Total RNA Mini SI Isolation Spin-Kit (Applichem) and 
used for reverse transcription (Superscript III RT; Invitrogen). The 
PCR conditions were as follows: initial dénaturation at 95 °C for 
10 min, followed by 40 cycles of dénaturation (95 °C, 30 s), anneal­
ing (55 °C, 60 s), and elongation (72 °C, 60 s).
Immunohistochemistiy
Tissue expression of the MAO isoenzymes was determined from 
frozen sections o f rat hearts using MAO-A (ab126751; Abeam; 1:50) 
and MAO-B (ab125010; Abeam; 1:50) primary antibodies and Texas 
Red labeled secondary goat anti-rabbit antibody (SC2780,1:200; 
Santa Cruz), respectively. Nuclear staining was performed with 
DAPI (SC3598; Santa Cruz). The slides were examined on an Olym­
pus Fluoview FV1000 confocal microscope (DAPI, excitation 
405 nm and emission 461 nm; Texas Red, excitation 543 nm and 
emission 612 nm). Images were analyzed with Icy 1.6.1.1, a free 
open-source image analysis software developed by the Quantita­
tive Image Analysis Unit at Institut Pasteur Paris (de Chaumont 
et al. 2012).
The expression o f the isoenzymes in rat aortas was determined 
on formalin-fixed, paraffin-embedded tissue sections, using the 
same primary antibodies and Novolinlc Polymer Detection System 
(Novocastra, RE7150-K). These detection systems contain perox­
idase block, protein block, post-primary block, Novolink polymer, 
DAB chromogen, Novolink DAB substrate buffer (polymer), and 
hematoxylin.
Statistics
Data are the mean ± SEM, and were analyzed using a one-way 
ANOVA or Student t test, where appropriate. Post-hoc compari­
sons among the groups was performed using the Tukey test. Data 
analysis of the dose-effect response curves was performed using 
the ANOVA F test (comparisons of bottom and top values, EC50, 
and the Hill slope). Values ofp<  0.05 were considered statistically 
significant.
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g. 1. Monoamine oxidase (MAO)-mediated H20 2 production and endothelial dysfunction in diseased vs. normal vascular preparations.
) Blood glucose levels in diabetic rats (DIAB) compared with the controls (CTL); n = 6 rats; \  p < 0.05. (B) Aortic H20 2 formation measured 
ing the ferrous oxidation -  xylenol orange assay, n = 6 rats; *, p < 0.05 for DIAB vs. CTL; #‘-3, p < 0.05 for DLAB+MAO inhibitors vs. DIAB. (C 
id D) Acetylcholine-induced relaxation in phenylephrine-preconstricted rat aortic segments from the DIAB group and the CTL group in the 
esence or absence of clorgyline (C) or selegiline (D); n = 6 rats; *, p < 0.05 for DIAB vs. CTL. CLORG, clorgyline (10 (imol/L; MAO-A inhibitor); 
•LEG, selegiline (10 jxmol/L; MAO-B inhibitor); #, p < 0.05 with and without CLORG and SELEG.
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Results
MAO is a mediator of endotlielial dysfunction in the 
STZ-induced diabetic rat model
The role of MAOs as sources of ROS in the vascular system was 
studied in aortic rings harvested from diabetic rats and compared 
with the control animals. Experiments were performed 2 months 
after diabetes was induced, and the development of glycemia in 
the diabetic rats was compared with the control animals (Fig. 1A). 
As dem onstrated with the FOX assay, the am ount o f H20 2 produc­
tion was significantly higher in vascular segments isolated from 
the diabetic as compared with the non-diabetic group. Incubation 
for 30 min with the irreversible MAO inhibitors (10 (xmol/L clor­
gyline or selegiline) partially restored the H20 2 levels (Fig. IB). In 
separate experim ents, the endothelium -dependent relaxation 
(EDR) of vascular segments from the diseased vs. the control ani­
mals was assessed. EDR was significantly attenuated in vascular 
rings from diabetic rats, and this effect was inhibited in the pres­
ence of either the MAO-A inhibitor clorgyline (Fig. 1C) or the 
MAO-B inhibitor selegiline (Fig. ID). Of note, the drugs had no 
effect on vascular reactivity in the control segments.
Vascular expression of MAO-A and -B isoforms is increased 
in the STZ-induced diabetic rat model
Since, in organ-bath experiments, incubation with either MAO 
inhibitor had no effect on vascular reactivity of the aortic rings 
harvested from  the control group, we hypothesized tha t both
isoforms are induced only in diseased animals. To address this 
hypothesis, we determ ined the expression of MAO-A and MAO-B 
by RT-PCR and imm unohistology in aortas isolated from rats with 
or without diabetes. In non-diabetic animals, the expression of 
MAO-B isoform, as judged from the difference in Cx values as well 
as from the intensity of the DAB staining, was more abundant 
than the MAO-A isoform (Fig. 2A). mRNA expression of both MAO 
isoforms showed an almost 2-fold increase (Fig. 2B) in aortic seg­
ments isolated from STZ-induced diabetic rats compared with the 
controls. To determ ine w hether mRNA induction also translates 
into changes in protein expression in aortic rings, imm unohistol­
ogy was also performed. As shown by the DAB staining in Fig. 2C, 
the MAO-B isoform was significantly more expressed in vascular 
rings harvested from diabetic animals as compared with the con­
trol group.
Myocardial expression o f MAO-B (but not o f MAO-A) 
isoform is increased in the STZ-induced diabetic rat model
To investigate w hether the up-regulation of MAOs also occurs in 
the heart as well as the vessels, we further performed im m uno­
fluorescence studies in myocardial samples isolated from diabetic 
and non-diabetic rats. Interestingly, no difference in the expres­
sion of MAO-A isoform could be detected between the diseased 
and control animals (Fig. 3). However, the opposite results were 
found for the MAO-B isoform expression, where the intensity of 
the fluorescent signal was significantly higher in heart samples
-4 Published by NRC Research Press
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Fig. 2. Monoamine oxidase (MAO) expression in vascular preparations from STZ-induced diabetic (DIAB) and non-diabetic (CTL) rats. Aortic 
segments from rats with or without diabetes. (A) Real-time (RT)-PCR (mRNA expression, 2~áCr) for MAO-A and MAO-B relative to the 
housekeeping gene EEF2a in aortic segments from control animals; n = 4 rats; *, p < 0.05. (B) RT-PCR (fold increase) for MAO-A and MAO-B 
relative to EEF2a in aortic segments from DIAB vs. CTL; n = 4 rats; *, p < 0.05. (C) Immunohistology for MAO-A and MAO-B in diabetic (DIAB) 
and control (CTL) aortic segments.
MAO A - CTL МАО В - CTL
MAO A - DIAB
harvested from the diabetic rats by comparison with the controls 
(Fig. 4).
Discussion
The major finding of our study is that MAOs contribute to the 
development of oxidative-stress-mediated endothelial dysfunc­
tion in experim ental diabetes.
From our organ-bath experim ents, we report a significant 
reduction in  the endothelium -dependent relaxation o f vascular 
segm ents in diabetic anim als com pared w ith the controls. In­
cubation w ith the irreversible MAO inhibitors (clorgyline for 
MAO-A and selegiline for MAO-B) partially restored the endothelium- 
dependent relaxation, suggesting a role o f both isoforms as medi­
ators o f endothelial dysfunction in this experimental model. This 
observation is in agreement with our previous findings in 2 m u­
rine models o f acute (a single injection of lipopolysacharride, i.p.) 
and chronic (2 weeks adm inistration of angiotensin II, via m ini­
pumps) oxidative stress. Accordingly, we reported that high levels 
of either lipopolysaccharide or angiotensin II led to overexpres­
sion of both MAO isoforms, with a subsequent increase in ROS 
production and im pairm ent o f vascular relaxation (Sturza et al. 
2013a). In another study, we have also dem onstrated that ex-vivo 
pretreatm ent w ith the same MAO inhibitors attenuated the endo­
thelial dysfunction in aortic rings harvested from spontaneously 
hypertensive rats (Sturza et al. 2013b). It has been previously re­
ported in the literature that treatm ent w ith angiotensin II con­
verting enzyme inhibitors reduced MAO activity, suggesting that
activation of the renin-angiotensin-aldosterone system may be 
responsible for the enzymatic induction (Raasch et al. 2002). Fur­
thermore, in-vitro or in-vivo application of selegiline, the irrevers­
ible MAO-B inhibitor, elicited vasodilatation via an increase in the 
am ount of nitric oxide in brain tissue and cerebral blood vessels 
(Shiva 2010).
We have also shown in this study that diabetes elicited a signif­
icant increase in the am ount of H20 2 generated in vascular prep­
arations via this mitochondrial enzyme (MAO) as determined by 
the FOX assay. In fact, type I experimental diabetes elicited a 
4-fold increase in the H20 2 production in aortic rings, whereas 
incubation (30 min) with MAO inhibitors reduced the am ount of 
ROS by 50%. These data are in agreement with those reported in an 
experimental model of type-2 diabetes, the Zucker diabetic fatty 
rat, where a significant (albeit less im portant as compared with 
the type-1 model of diabetes) H20 2 increase was found in the vas­
cular segments. Similar to what we have shown here, ex-vivo in­
cubation of aortic rings from Zucker diabetic fatty rats with MAO 
inhibitors diminished the oxidative stress by more than 50% 
(Sturza et al. 2014). Clearly, in both models of diabetes, the contri­
bution of other mitochondrial and cellular sources of ROS to the 
oxidative stress cannot be ruled out. In the cardiovascular system, 
NADPH oxidases and xanthine oxidase are prominent sources of 
oxidative stress and were reported to be overexpressed in diabe­
tes, w ith a subsequent increase in H20 2 production (Brandes and 
Schroder 2008; Xia et al. 2014).
-к Published by NRC Research Press
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Fig. 3. Monoamine oxidase (MAO)-A expression in heart samples from STZ-induced diabetic (DIAB) and non-diabetic (CTL) rats. 
Immunofluorescence: red, anti-MAO-A antibody: blue, DAPI.
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The alleviation of oxidative stress via MAO inhibition, however, 
raises 2 im portant questions: (i) do MAO inhibitors act as H20 2 
scavengers, and (it) is there is a cross-talk between MAO inhibitors 
and the other cellular ROS sources? In our previous study per­
formed in mice, we have unequivocally proven that irreversible 
MAO inhibitors (clorgyline, selegiline) neither acted as H20 2 scav­
engers nor potentiated xanthine oxidase and NADPH oxidase 
(Noxl, Nox2, and Nox4)-driven H20 2 form ation (Sturza et al. 
2013a). In this model, we showed that the induction of vascular 
MAO is mediated by NF-кВ and phosphatidylinositide 3-kinase, 
and proposed a pathophysiological sequence that could be re­
sponsible for the MAO-related endothelial dysfunction (Duicu 
et al. 2013).
Another im portant finding of this study is that in the control 
animals, MAO inhibition did not interfere with H20 2 production 
and vascular reactivity, suggesting that in basal conditions, MAO 
activity is reduced and the am ount of ROS produced is low, and 
thus unable to im pair endothelial function.
Last bu t no t least, we showed here, for the first time, that 
MAO-B is the dom inant isoform that is upregulated in both vas­
cular preparations and heart samples harvested from diabetic an­
imals. Both rat and hum an MAO-B have been reported to increase 
in the brain w ith advancing age (reviewed in Edmondson 2014); 
w hether the same holds true for the vascular system remains to be 
demonstrated.
The increased generation of ROS in the cardiovascular system in 
the setting of diabetes has been systematically reported. Classi­
cally, the major pathways responsible for overproduction of ROS 
are represented by the following: the polyol pathway (Toth et al. 
2007); the increased formation of advanced glycation end-products 
and their receptors (Singh et al. 2014); the activation of protein 
kinase C (PKC) (Kizub et al. 2014); and the overactivity of the hexo- 
samine pathway (Giacco and Brownlee 2010). The cellular sources 
of ROS associated w ith these biochemical pathways are repre­
sented by NADPH oxidases, the respiratory chain, and eNOS un­
coupling. Here we have dem onstrated that MAOs with 2 isoforms,
-à Published by NRC Research Press
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Fig. 4. Monoamine oxidase (MAO)-B expression in heart samples from STZ-induced diabetic (DIAB) and non-diabetic (CTL) rats. 
Immunefluorescence: red, anti-MAO-B antibody; blue, DAPI.
МАО В - CTL МАО В - DIAB
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МАО В - CTL МАО В - DIAB
60x 60x
МАО В - CTL МАО В - DIAB
A and B, are also im portant contributors to oxidative stress in 
experim ental diabetes. However, in this respect we acknowledge 
at least 2 lim itations of our study; first, we did not assess the 
effects of increased MAO on m itochondrial function; and second, 
the potentially deleterious effects o f the other 2 by-products of 
MAO’s catalytic cycle (ammonia and aldehydes) were not ad­
dressed. The form er issue may become im portant in the setting of 
diabetes and in-line w ith the statem ent claiming that H20 2 gen­
erated via the MAO-B isoform could be more destructive than that 
produced by MAO-A (Edmondson 2014).
As previously mentioned, MAOs have been extensively studied 
for their involvement in the pathogenesis of neurodegenerative 
and psychiatric diseases (Yamada and Yasuhara 2004), and an 
im portan t therapeu tic  arm am entarium  of MAO inhibitors 
are available for the treatm ent of several pathologies, including 
Parkinson’s disease, affective disorders, stroke, and senescence 
(Carradori and Petzer 2015). On the other and, diabetes has been 
recently associated with depression (Gupta et al. 2014), Parkin­
son’s disease, and Alzheimer’s disease (Hölscher 2014) as major 
complications of impaired neurotransmission. Bearing in mind
that reversible MAO-B inhibitors represent an important class of 
drugs largely indicated for their beneficial effects (including their 
neuroprotective properties) in psychiatric and neurological dis­
eases (Al-Nuaimi et al. 2012; Song et al. 2013), the observation that 
diabetes mainly increases the expression of the MAO-B isoform 
appears to be relevant as potential therapeutic target in this com­
plex metabolic disease.
Interestingly, it has been recently reported that pioglitazone, a 
widely employed anti-diabetic drug, acts as a specific and revers­
ible inhibitor of hum an MAO-B (Binda ct al. 2011). W hether dia­
betic patients treated with pioglitazone are less prone to develop 
endothelial dysfunction remains to be further clarified.
Nevertheless, the hypothesis that the decrease in MAO-mediated 
tissue injury could be protective in human vascular and cardiac 
samples harvested from diabetic patients clearly warrants further 
investigation (Duicu et al. 2014).
Conclusions
In conclusion, while both isoforms of MAO are expressed in the 
rat cardiovascular system, it is the MAO-B isoform that is mainly
Published by NRC Research Press
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induced in the experimental model of STZ-induced diabetes. 
MAO-induced endothelial dysfunction was partly mediated by 
H20 2, and ex-vivo inhibition of MAOs reasonably restored the 
normal function in diabetic vascular preparations. Monoamine 
oxidases are novel mediators of endothelial dysfunction in the 
experimental rat model of type-I diabetes.
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